» Authors » Robin Hull

Robin Hull

Explore the profile of Robin Hull including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 11
Citations 138
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Cockayne S, Rodgers S, Green L, Fairhurst C, Adamson J, Scantlebury A, et al.
Health Technol Assess . 2017 Jun; 21(24):1-198. PMID: 28621259
Background: Falls are a serious cause of morbidity and cost to individuals and society. Evidence suggests that foot problems and inappropriate footwear may increase the risk of falling. Podiatric interventions...
2.
Cockayne S, Fairhurst C, Adamson J, Hewitt C, Hull R, Hicks K, et al.
Trials . 2017 Mar; 18(1):144. PMID: 28351376
Background: Randomised controlled trials are generally regarded as the 'gold standard' experimental design to determine the effectiveness of an intervention. Unfortunately, many trials either fail to recruit sufficient numbers of...
3.
Cockayne S, Adamson J, Corbacho Martin B, Fairhurst C, Hewitt C, Hicks K, et al.
BMJ Open . 2014 Dec; 4(12):e006977. PMID: 25518875
Introduction: Falls and fall-related injuries are a serious cause of morbidity and cost to society. Foot problems and inappropriate footwear may increase the risk of falls; therefore podiatric interventions may...
4.
Walton-Moss B, ONeill S, Holland W, Hull R, Marineau L
Collegian . 2012 Oct; 19(3):171-6. PMID: 23101351
In the current educational environment, increasing numbers of advanced practice nursing (APN) students compete for decreasing numbers of clinical sites where patient safety is paramount. Clinical simulations with high-fidelity human...
5.
Page M, Stebbings R, Berry N, Hull R, Ferguson D, Davis L, et al.
Retrovirology . 2012 Jul; 9:56. PMID: 22799593
Background: Current data suggest that an efficacious human immunodeficiency virus type 1 (HIV-1) vaccine should elicit both adaptive humoral and cell mediated immune responses. Such a vaccine will also need...
6.
Berry N, Stebbings R, Ferguson D, Ham C, Alden J, Brown S, et al.
J Gen Virol . 2008 Aug; 89(Pt 9):2240-2251. PMID: 18753233
Vaccination with live attenuated simian immunodeficiency virus (SIVmacC8) confers potent, reproducible protection against homologous wild-type virus challenge (SIVmacJ5). The ability of SIVmacC8 to confer resistance to superinfection with an uncloned...
7.
Stebbings R, Berry N, Waldmann H, Bird P, Hale G, Stott J, et al.
J Virol . 2005 Sep; 79(19):12264-72. PMID: 16160152
In order to test the hypothesis that CD8+ cytotoxic T lymphocytes mediate protection against acute superinfection, we depleted >99% of CD8+ lymphocytes in live attenuated simian immunodeficiency virus macC8 (SIVmacC8)...
8.
Stebbings R, Berry N, Stott J, Hull R, Walker B, Lines J, et al.
Virology . 2004 Nov; 330(1):249-60. PMID: 15527850
The identification of mechanisms that prevent infection with human immunodeficiency virus (HIV) or simian immunodeficiency virus (SIV) would facilitate the development of an effective AIDS vaccine. In time-course experiments, protection...
9.
Stebbings R, Almond N, Stott E, Berry N, Hull R, Lines J, et al.
Virology . 2002 Jun; 296(2):338-53. PMID: 12069532
To determine whether attenuated simian immunodeficiency virus (SIV) vaccines confer protection against superinfection via secondary cellular immune responses, we searched for markers of immune activation following rechallenge. Productive infection with...
10.
Canto-Nogues C, Jones S, Sangster R, Silvera P, Hull R, Cook R, et al.
J Gen Virol . 2001 Aug; 82(Pt 9):2225-2234. PMID: 11514733
The distribution of virus-infected cells in cynomolgus macaques was determined at 4, 7, 14 and 28 days following intravenous challenge with 1000 TCID(50) of the wild-type simian immunodeficiency virus SIVmacJ5...